Glucotrack

01/10/2025

Glucotrack's Continuous Blood Glucose Monitor, or CBGM, has the potential to last THREE years.

An ability that is unsurpassed in the world of glucose monitoring.

You might ask yourself; how do we know the Glucotrack CBGM is capable of three-year monitoring? Well, we're not reinventing the wheel. We're standing on the shoulders of giants.

Mark Tapsak, VP of Sensor Technology at GlucoTrack, is here to tell you.

For more information on our human clinical study of our CBGM, visit https://glucotrack.com/glucotrack-announces-start-of-enrollment-for-human-clinical-study-of-continuous-blood-glucose-monitor/

12/16/2024

Does the market really need another Continuous Glucose Monitor?

At Glucotrack, we don’t believe in simply adding another option. We’re re-writing the rules of glucose monitoring, delivering bold solutions that address the unmet needs of millions of people living with diabetes.

In a recent study on the acceptance of the Glucotrack CBGM among people living with type 1 and type 2 diabetes, we found that out of 757 respondents using a variety of insulin regimens, there was a positive sentiment, with over 50% of people interested in acquiring the product.

Learn more, at https://glucotrack.com/about-us/.

12/03/2024

Glucotrack Announces Start Of Enrollment For Human Clinical Study Of Continuous Blood Glucose Monitor!

Listen as Glucotrack CEO, Paul Goode, PhD, speaks about what this means for the company.

For more information, read our latest press release,
https://glucotrack.com/glucotrack-announces-start-of-enrollment-for-human-clinical-study-of-continuous-blood-glucose-monitor/

12/03/2024

Patient enrollment for our first short-term human clinical study is now underway! Read the press release:

Stay informed. Discover the newest updates and developments at Glucotrack and the steps we're taking to revolutionize glycemic management.

11/21/2024

Exciting news 👏 Read our latest press release about the closing of a successful $10M public offering to advance our long-term implantable continuous glucose monitoring technology for diabetes care! Learn more: https://glucotrack.com/investor-relations/press-releases/

Stay informed. Discover the newest updates and developments at Glucotrack and the steps we're taking to revolutionize glycemic management.

11/18/2024

Hear CEO Paul Goode talk about our innovative approach to blood glucose monitoring https://www.msn.com/en-us/health/medical/simplifying-diabetes-with-an-implantable-cgm-paul-v-goode-phd-glucotrack-ceo/vi-AA1ttPyv?ocid=socialshare Ari Zoldan

Paul V. Goode, PhD, President and CEO of Glucotrack, discusses a new approach to diabetes management: an implantable CGM device that reduces the need for daily adjustments. Learn about this convenient outpatient procedure, which offers up to three years of hassle-free CGM use for diabetes patients.

10/08/2024

Living with diabetes requires constant management and monitoring.

What if there was a way to make this simpler, more automatic, and less burdensome for the more than 38 million Americans living with diabetes?

Glucotrack is pioneering groundbreaking glucose monitoring solutions.

We aim to improve the quality of life and release the millions of people who feel constrained by traditional CGM by developing technology that establishes a new level of real-time accuracy, increased convenience, and greater independence.

Learn more about Glucotrack today, https://loom.ly/tmJV-Rc

07/30/2024

Watch our new corporate video to learn how we're working toward revolutionizing continuous glucose monitoring. Visit glucotrack.com to see how we’re making a difference.

06/26/2024

At Glucotrack, we are dedicated to reducing the daily burden of glucose monitoring by creating cutting-edge technologies that enhance the lives of people living with diabetes. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering. Visit our website at glucotrack.com to learn more.

06/03/2024

Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that its implantable continuous glucose monitor has successfully completed 30 days of a 60-day long-term preclinical study on measuring glucose in the epidural space.

https://glucotrack.com/glucotracks-epidural-glucose-monitoring-sensor-demonstrates-successful-30-day-safety-performance-in-long-term-preclinical-study/